ESPR
Esperion Therapeutics Inc
NASDAQ: ESPR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$3.12
+0.32% today
Updated 2026-06-02
Market cap
$805.76M
P/E ratio
0.00
P/S ratio
1.93x
EPS (TTM)
$0.00
Dividend yield
—
52W range
$1 – $4
Volume
13.1M
Esperion Therapeutics Inc (ESPR) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$3.12
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.1B | $0.3B | $0.4B | $0.5B | $0.5B | $0.6B | $0.6B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 12.12% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -1.78%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.